New Research Underway to Examine Biological Mechanism That Cause Cataracts

Researchers at the University of Arizona College of Medicine – Tucson have started to conduct a study to investigate the biological mechanisms that cause cataracts in the aim of developing new, nonsurgical treatments.

New Research Underway to Examine Biological Mechanism That Cause Cataracts
February 07, 2022
LensGen Receives IDE Approval from FDA for Juvene® Presbyopia-Correcting Intraocular Lens

LensGen, Inc., a privately held ophthalmic medical device company, announced that the FDA has granted an Investigational Device Exemption (IDE) to begin a pivotal trial of its Juvene intraocular lens for cataract patients.

LensGen Receives IDE Approval from FDA for Juvene® Presbyopia-Correcting Intraocular Lens
December 01, 2021
LayerBio Granted U.S. Patent for OcuRing Drug Delivery Platform

LayerBio announced that the United States Patent and Trademark Office (USPTO) has issued US Patent No. 11,185,441 for its OcuRing Drug Delivery Platform.

LayerBio Granted U.S. Patent for OcuRing Drug Delivery Platform
December 02, 2021
Revolutionary Drug Treatment For Cataracts Shows Extremely Positive Lab Results

A revolutionary new treatment for cataracts has shown extremely positive results in laboratory tests, giving hope that the condition, which currently can only be cured with surgery, could soon be treated with drugs.

Revolutionary Drug Treatment For Cataracts Shows Extremely Positive Lab Results
May 18, 2022
New Study: Cataract Surgery Lowers the Risk of Dementia, Alzheimer’s Disease

Cataracts affect most older adults at risk for dementia, and new research shows that cataract surgery is linked to a lower risk of dementia.

New Study: Cataract Surgery Lowers the Risk of Dementia, Alzheimer’s Disease
December 07, 2021
AcuFocus Receives Approvable Letter From FDA for IC-8 Small Aperture IOL

AcuFocus announced that it has received an Approvable Letter from the FDA for its IC-8 small aperture IOL, which is designed for cataract patients.

AcuFocus Receives Approvable Letter From FDA for IC-8 Small Aperture IOL
December 08, 2021
LENSAR Announces FDA Acceptance of 510(k) Submission for ALLY Adaptive Cataract Treatment System

LENSAR announced that the U.S. Food and Drug Administration (FDA) has accepted its 510(k) submission for its next-generation ALLY Adaptive Cataract Treatment System for substantive review.

LENSAR Announces FDA Acceptance of 510(k) Submission for ALLY Adaptive Cataract Treatment System
March 02, 2022
Lensar Receives FDA Clearance of ALLY Adaptive Cataract Treatment System

Lensar announced FDA 510(k) clearance for its ALLY Adaptive Cataract Treatment System. ALLY is the first FDA-cleared platform to enable cataract surgeons to complete femtosecond-laser-assisted cataract surgery procedure in a single, sterile environment.

Lensar Receives FDA Clearance of ALLY Adaptive Cataract Treatment System
June 14, 2022
Tecnis Synergy IOL Provides Good Vision at All Distances in Refractive Lens Exchange

Bilateral implantation of the Tecnis Synergy IOL showed “very good” performence at all distances at 3 months of follow-up.

Tecnis Synergy IOL Provides Good Vision at All Distances in Refractive Lens Exchange
December 28, 2021
Rayner Expands Further into Europe with Direct Presence in France

Rayner announced its direct entry into the French cataract and refractive market. Based out of Lille in the Hauts-de-France region, Rayner has a growing team of ophthalmic specialist area managers focused on delivering service and support.

Rayner Expands Further into Europe with Direct Presence in France
July 18, 2022
Daha fazla